TY - JOUR
T1 - Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron
AU - Powers, Jacquelyn M.
AU - Shamoun, Mark
AU - McCavit, Timothy L.
AU - Adix, Leah
AU - Buchanan, George R.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
AB - Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
KW - heavy menstrual bleeding
KW - inflammatory bowel disease
KW - menorrhagia
KW - nutritional
UR - http://www.scopus.com/inward/record.url?scp=85006175128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006175128&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2016.09.053
DO - 10.1016/j.jpeds.2016.09.053
M3 - Article
C2 - 27776750
AN - SCOPUS:85006175128
SN - 0022-3476
VL - 180
SP - 212
EP - 216
JO - Journal of Pediatrics
JF - Journal of Pediatrics
ER -